Diagnosis and Management of Rare Immune-Related Adverse Events.

This article reviews the diagnosis and management of rare ocular, hematological, luminal gastrointestinal, and rheumatological toxicities arising from ICPi treatment. KEY POINTS: As the use of immune checkpoint inhibitors (ICPis) becomes more common, the number of rare immune-related adverse events (irAEs) will increase. A high level of suspicion is required to identify and treat these toxicities.Although it can be difficult to definitively attribute rare irAEs to ICPis, a temporal and mechanistic relationship and the absence of other etiologies should make the treating physician suspicious for a rare irAE.Certain rare irAEs, such as celiac disease, do not require treatment with glucocorticoids. Thus, differentiating this irAE from other gastrointestinal irAEs has important implications for treatment.
PMID: 31694890 [PubMed - as supplied by publisher]

Source: The Oncologist - November 5, 2019 Category: Cancer & Oncology Authors: Schoenfeld SR, Aronow ME, Leaf RK, Dougan M, Reynolds KL Tags: Oncologist Source Type: research